Company Profile
Tarsus Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Tarsus Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Tarsus Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Tarsus Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Tarsus Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
TARS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Tarsus’s catalysts are XDEMVY launch execution and whether the ophthalmology franchise can keep expanding into more prescribers and more patients. The market will watch for evidence that the commercial ramp is still early rather than already mature.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Source: Tarsus Pharmaceuticals
- 02
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Source: Tarsus Pharmaceuticals
- 03
Tarsus to Participate in Upcoming Investor Conference
Source: Tarsus Pharmaceuticals
- 04
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
Source: Tarsus Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.